0LB2 Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0LB2 from our risk checks.
Supernus Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$26.76 |
52 Week High | US$35.33 |
52 Week Low | US$22.54 |
Beta | 0.93 |
11 Month Change | -3.98% |
3 Month Change | -18.51% |
1 Year Change | -17.84% |
33 Year Change | -19.25% |
5 Year Change | -26.03% |
Change since IPO | -35.44% |
Recent News & Updates
Recent updates
Shareholder Returns
0LB2 | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 1.7% | -0.3% | 1.1% |
1Y | -17.8% | 10.1% | 8.1% |
Return vs Industry: 0LB2 underperformed the UK Pharmaceuticals industry which returned 10.1% over the past year.
Return vs Market: 0LB2 underperformed the UK Market which returned 8.1% over the past year.
Price Volatility
0LB2 volatility | |
---|---|
0LB2 Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 8.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0LB2's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0LB2's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 652 | Jack Khattar | www.supernus.com |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
Supernus Pharmaceuticals, Inc. Fundamentals Summary
0LB2 fundamental statistics | |
---|---|
Market cap | US$1.49b |
Earnings (TTM) | -US$15.51m |
Revenue (TTM) | US$597.40m |
2.5x
P/S Ratio-95.9x
P/E RatioIs 0LB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0LB2 income statement (TTM) | |
---|---|
Revenue | US$597.40m |
Cost of Revenue | US$76.63m |
Gross Profit | US$520.77m |
Other Expenses | US$536.28m |
Earnings | -US$15.51m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.28 |
Gross Margin | 87.17% |
Net Profit Margin | -2.60% |
Debt/Equity Ratio | 0% |
How did 0LB2 perform over the long term?
See historical performance and comparison